Headache News and Research

Latest Headache News and Research

Alkermes submits VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that it has submitted a supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) to the U.S. Food and Drug Administration (FDA) for approval as a treatment for opioid dependence. The company requested a priority review for its sNDA and if granted by the FDA, it would mean a six month review timeline.

13 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

Study supports use of Fisher Wallace Cranial Stimulator for treating depression, anxiety and insomnia

Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.

13 Apr 2010

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

People with no health insurance are less likely than the privately insured to receive proper treatment for their migraines, according to a study published in the April 13, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

13 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

12 Apr 2010

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

GenVec, Inc. announced that encouraging clinical and preclinical malaria vaccine data were presented at the Keystone Symposium -- Malaria: New Approaches to Understanding Host-Parasite Interactions taking place April 11-16, 2010 in Copper Mountain, Colorado.

12 Apr 2010

Team of neurologists from the U.S. face Canadian neurologists in annual "Neurobowl"

In a competition modeled after TV quiz shows, a team of neurologists from the United States will face Canadian neurologists in the annual "Neurobowl®" on April 11.

12 Apr 2010

People without migraines can filter out more visual noise: Study

When people feel the onset of a migraine headache, they may head to a dark, quiet room to rest. This instinct may be sound: A new study suggests that even without the headache, migraine sufferers may process visual cues better in an environment with few visual distractions.

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

MAP Pharmaceuticals to present additional data from FREEDOM-301 Phase 3 trial of LEVADEX at AAN meeting

MAP Pharmaceuticals, Inc. today announced the Company will present additional post-hoc analyses from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy in two patient subpopulations that are often difficult to treat with current triptan migraine therapies: menstrual migraine and migraine with allodynia.

7 Apr 2010

Are Australians popping too many pills?

These reports have emerged from a Daily Telegraph investigation. Australian Medical Association vice president, GP and former Pharmaceutical Benefits Advisory Committee member Dr Steve Hambleton said the resons for these trends may include the increasing population of the aged, newer medicines as well as a rise in chronic lifestyle ailments like diabetes and high blood pressure.

5 Apr 2010

2010 Internal Medicine conference at Toronto Convention Center

More than 5,000 internists (adult medicine specialists), subspecialists, medical students, and allied health professionals will meet in Toronto, Canada, for Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP), April 22 - 24 (Thursday - Saturday), at the Toronto Convention Center.

2 Apr 2010

Gastrointestinal tract disorders GERD and IBS interlinked

Gastroesophageal reflux disorder (GERD) and irritable bowel syndrome (IBS) are two very common disorders affecting the gastrointestinal tract. About 10% of the population experience daily discomfort from reflux of gastric contents into the esophagus. More than 10% of the population experience abdominal pain and disturbed bowel movement because of irritable bowel syndrome.

2 Apr 2010

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Santarus, Inc., a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc., the consumer healthcare subsidiary of Merck & Co., Inc., has commenced promotion of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its licensing agreement with Santarus for the over-the-counter (OTC) market in North America. The OTC heartburn market in the U.S. is estimated at approximately $1.8 billion based on data from market research firm Information Resources, Inc. and Santarus estimates.

2 Apr 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010